Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives

被引:59
作者
Abdul-Latif, Mohammed [1 ]
Townsend, Katherine [2 ]
Dearman, Charles [2 ]
Shiu, Kai-Keen [3 ]
Khan, Khurum [1 ,3 ]
机构
[1] North Middlesex Univ Hosp, Dept Oncol, Sterling Way, London N18 1QX, England
[2] Royal Marsden, Fulham Rd, London SW3 6JJ, England
[3] UCL, Canc Inst, Dept Med Oncol, 72 Huntly St, London WC1E 6AG, England
关键词
Immunotherapy; Gastrointestinal cancer; Review; Oesophageal; Gastric; Pancreatic; Colorectal; Hepatic; Biliary; Checkpoint inhibition; Vaccine; Adoptive cell therapy; T-CELL THERAPY; COMPREHENSIVE MOLECULAR CHARACTERIZATION; MISMATCH REPAIR-DEFICIENT; INDUCED KILLER-CELLS; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; SOLID TUMORS; PHASE-I; RECOMBINANT INTERLEUKIN-2;
D O I
10.1016/j.ctrv.2020.102030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastrointestinal cancers include colorectal, gastric, oesophageal, pancreatic and liver cancers. They continue to be a significant cause of mortality and morbidity worldwide. Current treatment strategies include chemotherapy, surgery, radiotherapy and targeted therapies. Immunotherapy has recently been incorporated in treatment regimens for some gastrointestinal malignancies and research into different immune modifying treatments is being carried out in this context. Approaches to immune modulation such as vaccination, adoptive cell therapy and checkpoint inhibition have shown varying clinical benefit, with most of the benefit seen in checkpoint inhibition. This review summarises recent advances and future direction of immunotherapy in patients with gastrointestinal malignancies.
引用
收藏
页数:18
相关论文
共 142 条
[1]   A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. [J].
Abou-Alfa, Ghassan K. ;
Chan, Stephen Lam ;
Furuse, Junji ;
Galle, Peter R. ;
Kelley, Robin Kate ;
Qin, Shukui ;
Armstrong, Jon ;
Darilay, Annie ;
Vlahovic, Gordana ;
Negro, Alejandra ;
Sangro, Bruno .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2]  
al VCe, 2019, ESMO WORLD GI C 2019
[3]   Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].
Alley, Evan W. ;
Lopez, Juanita ;
Santoro, Armando ;
Morosky, Anne ;
Saraf, Sanatan ;
Piperdi, Bilal ;
van Brummelen, Emilie .
LANCET ONCOLOGY, 2017, 18 (05) :623-630
[4]   CAR T-cell Therapy: A New Era in Cancer Immunotherapy [J].
Androulla, Miliotou N. ;
Lefkothea, Papadopoulou C. .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2018, 19 (01) :5-18
[5]  
[Anonymous], 1961, ACTA MED SCAND, V170, P128
[6]  
[Anonymous], 2017, J CLIN ONCOL S
[7]   Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer [J].
Aruga, Atsushi ;
Takeshita, Nobuhiro ;
Kotera, Yoshihito ;
Okuyama, Ryuji ;
Matsushita, Norimasa ;
Ohta, Takehiro ;
Takeda, Kazuyoshi ;
Yamamoto, Masakazu .
JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
[8]   Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer [J].
Aruga, Atsushi ;
Takeshita, Nobuhiro ;
Kotera, Yoshihito ;
Okuyama, Ryuji ;
Matsushita, Norimasa ;
Ohta, Takehiro ;
Takeda, Kazuyoshi ;
Yamamoto, Masakazu .
CLINICAL CANCER RESEARCH, 2013, 19 (08) :2224-2231
[9]  
Bang YJ, 2010, LANCET, V376, P1302
[10]   Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. [J].
Bang, Yung-Jue ;
Ueno, Makoto ;
Malka, David ;
Chung, Hyun Cheol ;
Nagrial, Adnan ;
Kelley, Robin Kate ;
Piha-Paul, Sarina Anne ;
Ros, Willeke ;
Italiano, Antoine ;
Nakagawa, Kazuhiko ;
Rugo, Hope S. ;
De Braud, Filippo G. ;
Varga, Andrea I. ;
Hansen, Aaron Richard ;
Gao, Chao ;
Krishnan, Suba ;
Norwood, Kevin ;
Doi, Toshihiko .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)